The VP-2 gene of mink enteritis parvovirus (MEV) was amplified by the polymerase chain reaction using MEV DNA isolated from the faeces of a naturally infected mink. Subsequently the VP-2 gene was cloned into a baculovirus expression vector. Recombinant baculoviruses were isolated and the MEV VP-2 gene product was characterized after expression in St9 insect cells. The MEV VP-2 product had the same size as that reported for the wild-type MEV VP-2 protein and was recognized by convalescent sera from MEV-infected mink and a panel of monoclonal antibodies reactive to MEV. Furthermore, the VP-2 protein was able to form parvovirus-like particles, which had haemagglutinating properties comparable with the wild-type MEV. The cloned VP-2 gene was sequenced and only five nucleotide differences were found after alignment with the known sequences of the MEV type 1 and type 2 isolates. Surprisingly, the VP-2 gene encoded a valine and a tyrosine at amino acid positions 232 and 234, identical to the situation found in MEV type 1, but at position 300 there was a valine which is a determinant of MEV type 2. Immunization of mink with approximately 40000 haemagglutinating units of recombinant MEV VP-2 induced a measurable antibody response as tested by haemagglutination inhibition. Furthermore, the immunized mink did not excrete virus and did not develop clinical disease upon challenge with a virulent isolate of MEV.
Introduction
Mink enteritis virus (MEV) belongs to the parvoviridae family and is further subgrouped under the feline parvoviruses together with feline panleukopenia virus, raccoon parvovirus and the canine parvovirus (CPV), all characterized as host range variants (Cotmore & Tattersall, 1987) . The feline parvoviruses are genetically, antigenically and pathogenically closely related, all causing acute disease (Siegl, 1984; Parrish et al., 1988; Parrish, 1990) .
The MEV virion consists of a linear negative-sense single-stranded DNA of approximately 5 kb (Kariatsumari et al., 1991) encapsidated by three structural proteins, VP-1 (77"5K), VP-2 (63.5K) and VP-3 (63K) (Carman & Povey, 1983) . Based on the transcription data from minute virus of mice (Jongeneel et al., 1986) , t Present address: National Veterinary Laboratory, Btilowsvej 27, DK-1790 Copenhagen V, Denmark. the VP-1 and VP-2 structural proteins of MEV are presumably derived from differentially spliced mRNAs. In contrast, MEV VP-3 is generated by post-translational proteolytic processing of VP-2 and is present only in full virions (Paradiso et al., 1982) . VP-2 is the most abundant protein in the virion, approximately 50 copies are present (Cotmore & Tattersall, 1987) and there are on average 10 copies ofVP-1 (Paradiso et al., 1982) . The VP-2 and VP-3 amino acid sequences are fully contained in the VP-1 sequence, which in addition in its amino-terminal part contains a 15K amino acid region believed to be involved in stabilization of the virus genome inside the virion (Luo et al., 1988) .
MEV causes acute enteric disease in mink. The acutely induced enteritis was first observed in 1947 in Canada, with a mortality of up to 80 % of infected mink kits (Wills, 1952) , and thereafter it was reported from many parts of the world (Burger & Gotham, 1970) . In Denmark the disease was identified in 1958 (Knox, 1960) . More recently, by using monoclonal antibodies, DNA sequence analysis and other techniques several 0001-1809 © 1994 SGM different types of MEV have been identified (Parrish et al., 1982 (Parrish et al., , 1984 (Parrish et al., , 1988 ; however, no differences in the clinical cases have been reported.
Prophylactic vaccination against MEV is now widely used. The vaccines are mainly made from formalininactivated crude homogenates of cell culture-adapted virus strains. All antigenic types of MEV will induce solid immunity to other antigenic types of MEV as demonstrated in challenge tests (Parrish et al., 1984) . As only killed vaccines against MEV are now allowed in Denmark, the antigen content of the vaccine is crucial especially to overcome maternal immunity in young kits. At present this is achieved by using cell culture-adapted virus strains, but the amount of viral antigen present has not always proven to be sufficient (Uttenthal, 1988).
Here we employed the powerful baculovirus expression system to produce a protein expressed from an MEV VP-2 gene derived directly from a naturally MEVinfected Danish mink. The sequence of the MEV VP-2 gene was determined and the recombinant gene product was tested for resemblance to VP-2 derived from MEV in cell culture. Furthermore, the protective potential of VP-2 as a vaccine was tested by challenge with a virulent isolate of MEV.
Methods
Chemicals and reagents. All enzymes were obtained from Promega, Boehringer Mannheim, In Vitrogen or United States Biochemical. Plasmids were purchased from either Promega (pGEM-3Z) or In Vitrogen (pBlueBac fill).
[a~S]dATP and 125I-Protein A were obtained from Dupont. Synthetic oligonucleotides used for PCR amplification of the MEV VP-2 gene were synthesized by the Institute of Biotechnology (Lyngby, Denmark).
Bacteria. The Eseherichia coli strain Sure (Stratagene) was transformed as described by Maniatis et al. (1982) .
Cloning of the MEV VP-2 gene. MEV DNA was isolated from faeces from a naturally infected mink in Denmark in 1990 (MEV DK90). In short, the faeces were homogenized, frozen and thawed in TE (20 mMTris-HC1, 1 mM-EDTA, pH 8.8) and subjected to centrifugation at 950g for 15 rain. The MEV particles were then pelleted from the supernatant by ultracentrifugation (120000 g for 2 h). The pellet was dissolved in TE containing 1% SDS and proteinase K, incubated for 18 h at 37 °C, and phenol-chloroform-extracted twice followed by ethanol precipitation. The MEV VP-2 gene was amplified from the purified MEV DNA using PCR and two MEV-specific primers MEV,e~t 5" ATTCTAGACTTGCACCAATGG_GTGATGGA 3" (MEV nucleotides 493 to 513) and MEV~ght 5' ATTCTAGAGTATATTAATATA-ATTTTCTAGG 3' (MEV nucleotides 2239 to 2260).
The conditions for the PCR have been described previously (Alexandersen & Carpenter, 1991) . Nucleotide numbers are given according to Parrish et aL (1988) . The underlined G in the MEVle~t primer introduces a mutation in the amplified MEV VP-2 gene by substituting G for A, making the start codon for translation potentially better according to the consensus context proposed by Kozak (1983) . Both primers contain an Xbal restriction enzyme site (in bold), allowing direct cloning of the PCR product, after XbaI digestion, into the Nhel site of the baculovirus transfer vector pBlueBac fill (Vialard et al., 1990) . For sequencing, the amplified gene was cloned into the XbaI site of pGEM-3Z. Two different clones of the PCR-amplified MEV VP-2 gene were sequenced. These clones had identical nucleotide sequences. MEV-specific oligonucleotides, used for sequencing, were a generous gift from Colin Parrish, James A. Baker Institute of Animal Health, Cornell University, Ithaca, N.Y., U.S.A. Sequencing was performed as previously described (Bloom et al., 1988) .
Cells and viruses. Spodoptera frugiperda (Sf9) insect cells and Autographa californica nuclear polyhedrosis virus (AcNPV) were grown as previously described (Christensen et al., 1993) . Cell culture equipment was obtained from Nunc. Bluo-Gal was from Gibco/BRL. Antisera, monoclonal antibodies, cytospin preparations and immunofluorescence. The antiserum used was pooled sera from two MEVinfected mink. Monoclonal antibodies (MAbs) 8, F and H (Parrish et al., 1982) were a gift from Colin Parrish. Fluorescein isothiocyanateconjugated Protein A was obtained from Dakopats. Cytospins of Sf9 cells infected with recombinant AcNPV were made as described previously (Christensen et al., 1993) .
Construction of recombinant AcNPV. Pure recombinant AcNPV was produced as previously described (Christensen et al., 1993) .
PAGE and immunoblots.
Total cellular proteins were subjected to electrophoresis in 10 % acrylamide gels according to the procedure of Laemmli (1970) . Proteins were stained with Coomassie blue or blotted onto nitrocellulose membranes and detected as previously described (Christensen et at., 1993) .
Preparation ofMEV VP-2 immunogen. Sf9 cells were infected at high multiplicity (m.o.i. of 5). The infected cells were harvested 48 h postinfection (p.i.) and washed once in PBS. The cell pellet was frozen and thawed three times followed by three periods of 15 s sonication and cell debris was removed by low speed centrifugation. The cellular extract, designated MEV VP-2BAC, was inactivated by 15 rain ofu.v, irradiation before addition of adjuvant. The amount of haemagglutinating units (HAU) in the supernatant was determined using erythrocytes from the African green monkey (Cercopithecus aethiops) as previously described (Uttenthal, 1988) , The MEV VP-2BA c extract was adjusted to approximately 4x 104 HAU/vaccine dose and AIOH 3 (Superfos Biosector) was added as an adjuvant before immunization.
Immunization safety test. Six male mink of the wild-type coat colour (genotype A/A) were vaccinated subcutaneously with 1 ml of the MEV VP-2BAc-based vaccine and six mink with a commercially available killed MEV vaccine (United Vaccines; declared to contain a minimum of 15 000 HAU per dose). Seventeen days after the primary vaccination three animals in each group were revaccinated. Blood was collected at indicated time periods. Mink were killed 28 days after the initial vaccination to obtain organ material for pathological examination.
Vaccination of mink.
A vaccine comparable with the one used for the immunization safety test was used in the protection study. Ten black mink (genotype A/A) were vaccinated with this vaccine, seven were vaccinated with a commercially available vaccine and seven mink were not vaccinated. The animals were challenged 7 weeks after vaccination by the oronasal route using 0-8 ml of a 25% intestinal bomogenate from mink suffering from acute MEV infection. After challenge the mink were observed daily for clinical signs of disease. Virus shedding in faeces was measured daily 4 to 8 days p.i. Blood was collected before vaccination, 21 days post-vaccination and 7 days post-challenge. Eighteen days after challenge the animals were killed and blood and faeces were collected.
Haemagglutination assays. Haemagglutination (HA) and haemagglutination inhibition (HI) titres and secretion of virus were determined as previously described (Uttenthal, 1988) .
Electron microscopy. Electron microscopy was performed as previously described (Christensen et al., 1993) .
R e s u l t s

Cloning and sequence analysis of a M E V VP-2 gene
The MEV VP-2 gene was PCR-amplified from MEV D N A obtained from a Danish mink naturally infected with MEV in 1990. Subsequently, the amplified MEV VP-2 gene was cloned into the baculovirus transfer vector pBlueBac flII for production of recombinant baculovirus (rAcNPV).
Sequence analysis of the cloned gene revealed only five nucleotide differences when aligned with the known VP-2 gene sequences of either MEV type 1 or type 2 isolates (Table 1) (Parrish et al., 1988) . Interestingly, where there were nucleotide differences from MEV type 1, no 
* Nucleotide numbers are given according to Parrish et al. (1988) .
? Amino acid positions are only given if variation was found. differences from MEV type 2 were observed, and vice versa. Few of the differences introduced amino acid changes in the VP-2 protein. Surprisingly, the coding nucleotide differences predicted a valine at amino acid position 232 and a tyrosine at position 234 which are characteristic of the MEV type 1 isolate. However, the valine at position 300 of the VP-2 gene was identical to that of MEV type 2. Thus, it seems that at the amino acid level the MEV DK90 VP-2 gene is a little more related to MEV type 1 than to MEV type 2, but at the nucleotide level it is equally related to both of the MEV types.
Expression of M E V VP-2 by recombinant baculoviruses
Two MEV VP-2-expressing rAcNPVs were isolated (designated MEV5 VP-2Ae and M E V l l VP-2Ao ). S D S -P A G E of total lysates of m0nolayers of Sf9 cells infected at high multiplicities (m.o.i. around 5) with MEV5 VP2Ao or MEV11 VP-2Ae harvested 48 h p.i. showed a high level of expression of MEV VP-2 structural protein (Fig.  1 a) . The M r, as determined by SDS-PAGE, of the MEV VP-2 gene product was 63.5K; in agreement with the Mr reported for MEV VP-2 expressed after MEV infection in cell culture (Carman & Povey, 1983) . Analysis of the Coomassie blue-stained gel by laser densitometry suggested that 5 to 10 % of the total protein in the lysates was MEV VP-2, corresponding to 10 to 20 mg per 109 St9 cells. This yield is a little lower than those reported for baculovirus expression of Aleutian mink disease parvovirus or human B19 parvovirus structural proteins (Christensen et al., 1993; Brown et al., 1990) , Western blot analysis using sera from MEV-infected mink detected the 63"5K band (Fig. 1 b) . Thus, both of the recombinant baculoviruses expressed protein that had MEV-like antigenic properties. No bands of that size were detected in wild-type AcNPV-infected or uninfected Sf9 cells. Similarly, immunofluorescence analysis of SO cells infected with MEV5 VP-2A~ confirmed the specificity of the reaction seen by Western blotting and showed that MEV VP-2 was localized in the cytoplasm of the insect cells (data not shown).
Formation of MEV-like particles by rAcNPV-expressed M E V VP-2
To determine whether the MEV5 VP-2 gene product was able to form parvovirus-like particles, we infected Sf9 cells at high multiplicities with MEV5 VP-2Ac. The cells were harvested 48 h p.i., sonicated and the debris analysed by electron microscopy after ultracentrifugation through a sucrose cushion. M E V VP-2 expressed by MEV5 VP-2Ae was able to form icosahedral MEV-like capsids of approximately 25 nm diameter (Fig. 2a) . Incubation of the MEV-like capsids with a MEVreactive MAb, F (Parrish et at., 1982) , caused aggregation of the capsids (Fig. 2 b) . The two MEV type 1-reactive MAbs, 8 and H (Parrish et al., 1982) , did not cause any aggregation of the capsids (data not shown).
HI by MAbs
The supernatant obtained after sonication of the MEV VP-2Ao-infected Sf9 cells was able to haemagglutinate African green monkey erythrocytes in barbital/acetatebuffered saline pH 6.2. The titres obtained were approximately 109 HAU/109 Sf9 cells.
Antigenic analysis of the capsids by HI using the three MEV-reactive MAbs mentioned above and comparison with three recent, geographically distant, Danish MEV isolates showed a uniform reaction pattern (data not shown). MAb F reacts with all known types of MEV, whereas MAbs 8 and H react only with MEV type 1 isolates; no reaction was observed with the latter two MAbs, The current classification of MEV type 1 and type 2 isolates is based on these MAbs (Parrish et al., 1982) . By this definition all the Danish isolates and the rAcNPV VP-2 product are MEV type 2.
Safety test
In order to determine whether the recombinant baculovirus product had any severe side-effects when injected into mink, a safety experiment was performed. Two groups of mink were immunized with either the recombinant baculovirus VP-2 or a registered, killed MEV vaccine. The registered vaccine was a formalininactivated vaccine plus adjuvant with no other components. Seventeen days after initial vaccination three mink in each group were boosted with the same vaccine and then killed 28 days after the initial vaccination.
Both groups exhibited a weak antibody response after the initial vaccination. Following the second vaccination an increase was observed in both groups. The antibody titre in the group of animals vaccinated with the recombinant vaccine was higher after revaccination (HI titre 1280 to 10240) than that observed for the group receiving the registered vaccine (HI titre 40 to 320). Since we do not know the antigen dose or the effect of formalin on the antigenicity of the registered vaccine, the higher antibody response observed with the recombinant vaccine could be a result of a higher dose of antigen injected and/or that the antigenicity is better.
Histopathological examination of haematoxylin-and eosin-stained tissue sections of liver, kidney, spleen and mesenteric lymph node of mink from both vaccination groups showed no pathological effects.
hnmunization and challenge of mink
Ten mink were vaccinated using the baculovirusproduced MEV VP-2, seven mink were vaccinated using a commercial killed MEV vaccine and seven mink were left unvaccinated. After 7 weeks the three groups of mink were challenged with virulent MEV. Among the nonvaccinated animals five out of seven showed clinical signs of anorexia, creamy diarrhoea and intestinal desquamations in the faeces at day 5 p.i. No clinical signs were observed in any of the vaccinated mink.
All unvaccinated animals excreted virus in their faeces and virus excretion was detected on days 4 to 7 p.i. (Table 2) . No virus excretion could be detected after 8 days p.i. In the two groups of vaccinated animals no viral antigen was detected in the faeces in daily samples (Table 2) .
Serum was collected prior to vaccination, 21 days post-vaccination and 7 and 18 days after challenge. All samples were tested for antibodies to MEV by HI. Before 18-24 .... * The samples were tested in a sandwich ELISA as a 20 % suspension of faeces. t +, Positive; (+), weakly positive; -, negative; ND, not determined. Each sample was indexed relative to a known positive sample, signals > 20% relative to the known positive were regarded as positive.
:~ Animals were vaccinated 7 weeks prior to challenge. vaccination all animals had HI titres below 20, which is the threshold level of the testing system (Table 3) . At 3 weeks after vaccination all animals except the nonvaccinated group had an HI median titre of 320 (killed MEV group and MEV VP-2BA c group). Following challenge the median anti-MEV antibody titre in the non-vaccinated animals increased to 5120, and the corresponding median titres of the vaccinated groups were 160 to 320 (MEV VP-2BA c group) and 640 (killed MEV group).
Discussion
The baculovirus expression system has several advantages over other expression systems. It is possible to express biologically active proteins in large quantities and the products of baculovirus expression are often similar to their native counterparts in terms of biological activity, antigenicity and immunogenicity (Luckow & Summers, 1988 Lanford et aL, 1989 ; Christensen eta[., 1993) . In this report we have described the production of a recombinant vaccine to protect mink against MEV. The MEV VP-2 gene derived from a naturally MEV-infected mink was cloned and expressed in insect cells using a recombinant baculovirus expression vector. The resulting recombinant MEV VP-2 gene product conferred at least equivalent protection upon immunized mink compared with a commercial vaccine against MEV. Upon repeated vaccination, no pathological effects were observed in any of the animals. The MEV VP-2 structural protein was expressed in insect cells using a rAcNPV. The expressed product had the expected M,. of 63.5K (Carman & Povey, 1983) and was localized in the cytoplasm of the insect cells. MEV VP-3 was not observed in our preparations indicating, as suggested before (Paradiso et al., 1982) , that MEV viral DNA has to be present before proteolytic processing of VP-2 to VP-3 occurs. Alternatively, the necessary proteolytic enzyme may not be present in AcNPVinfected Sf9 cells. The MEV VP-2 protein was able to assemble into MEV-like empty capsids, demonstrating that the presence of MEV VP-1 is not necessary for capsid formation. Similar observations have been made in other parvoviruses (Brown et al., 1990; Christensen et al., 1993; Saliki et al., 1992) . The MEV-like capsids had haemagglutinating properties similar to those of cell culture-grown MEV.
Several types of MEV have been identified on the basis of their reaction with MAbs and gene analysis (Parrish et al., 1988 (Parrish et al., , 1982 . Typing of rAcNPV-expressed MEV capsids with MAbs indicated that the expressed MEV VP-2 gene product was MEV type 2-like. A similar reaction pattern was found for geographically distant MEV isolates in Denmark.
The MEV type 1 and type 2 isolates differ by 10 nucleotides in the VP-2 gene (Parrish et al., 1991) . Surprisingly, the sequence comparison of the cloned MEV VP-2 gene with the published MEV type 1 or MEV type 2 sequences revealed only five nucleotide differences from each respectively. One explanation for this could be that we cloned the VP-2 gene directly from MEVinfected mink whereas the other two MEV isolates were cloned after several passages in cell culture (Parrish et al., 1991) .
Few of the nucleotide differences introduced coding changes in the MEV VP-2 gene. In contrast to the typing results obtained using MAbs, the MEV VP-2 gene was at the amino acid level most closely related to that of MEV type 1. However, this observation can be explained by the presence of a valine at amino acid position 300 in the DK90 MEV VP-2 gene which is identical to the amino acid in MEV type 2. An alanine is found at position 300 in MEV type 1 and this probably forms part of the epitope recognized by MAbs 8 and H (Parrish et al., 1988) . Thus, the DK90 MEV isolate seems to share characteristics with both MEV type 1 and MEV type 2 isolates.
The level of protection conferred by the rAcNPV MEV VP-2 expressed product appeared to be at least equivalent to that achieved by a commercial vaccine against MEV. In the group of repeatedly vaccinated animals, higher antibody titres to MEV were found in the animals vaccinated with the recombinant vaccine than in those treated with registered vaccine. This is probably due to the higher antigen content of the recombinant vaccine or a better antigenicity because the recombinant vaccine was not formalin-inactivated. Following MEV challenge vaccinated animals show moderate increases in specific anti-MEV titres. Unvaccinated animals and those given inefficient prophylactic treatment display a more drastic increase in specific antibody titres (Uttenthal, 1988) . In this report only the unvaccinated animals had high titre 1 to 2 weeks after challenge. It was also observed that there was an increase of the titres in days 7 and 18 p.i. in the unvaccinated mink, whereas the vaccinated group generally seemed to have reached a steady level on day 7 p.i. All vaccinated animals were protected against clinical disease and did not excrete MEV in their faeces. In a recent CPV study in which dogs were immunized and challenged, it was found that the registered vaccine, which was a modifiedlive vaccine, induced a much higher anti-CPV antibody titre than that found in dogs vaccinated with a CPV VP-2 recombinant baculovirus protein (Saliki et al., 1992) . This difference between that study and ours was most likely caused by the fact that vaccines to MEV are killed vaccines whereas the vaccine used in the dog experiment was a modified-live vaccine.
Even after repeated vaccination no lesions were observed in histological sections of tissues from mink vaccinated with the killed MEV vaccine or the MEV VP-2 recombinant vaccine. Furthermore, no clinical signs were observed in vaccinated mink. Since mink are usually vaccinated only once and even repeated vaccinations did not seem to harm the animals, we conclude that the vaccination with the recombinant MEV VP-2 product is harmless.
In summary, MEV VP-2 expressed by rAcNPV assembled into parvovirus-like capsids, was not harmful when injected into mink, and was able to confer resistance to virulent MEV. Since the capsids produced are non-viable there is no need for the use of harsh inactivation procedures before vaccination.
